Merrimack Pharmaceuticals
MACK
#8368
Rank
NZ$0.38 B
Marketcap
NZ$26.19
Share price
0.00%
Change (1 day)
4.59%
Change (1 year)

Earnings for Merrimack Pharmaceuticals (MACK)

Earnings in 2024 (TTM): -NZ$3.71 Million

According to Merrimack Pharmaceuticals's latest financial reports the company's current earnings are N/A. In 2023 the company made an earning of -NZ$3.77 Million a decrease over its 2022 earnings that were of -NZ$3.77 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Merrimack Pharmaceuticals from 2010 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -NZ$3.71 Million-1.62%
2023 -NZ$3.77 Million0.09%
2022 -NZ$3.77 Million-16.9%
2021 -NZ$4.53 Million-49.89%
2020 -NZ$9.04 Million-75.39%
2019 -NZ$36.72 Million-68.58%
2018 -NZ$0.12 Billion-19.4%
2017 -NZ$0.15 Billion-36.46%
2016 -NZ$0.23 Billion2.54%
2015 -NZ$0.23 Billion96.78%
2014 -NZ$0.12 Billion-45.44%
2013 -NZ$0.21 Billion
2010 -NZ$80.38 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
NZ$15.75 B-402,944.62%๐Ÿ‡ซ๐Ÿ‡ท France
AVEO Oncology
AVEO
-NZ$50.27 Million 1,185.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Geron
GERN
-NZ$79.5 Million 1,932.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Clovis Oncology
CLVS
-NZ$0.38 Billion 9,523.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
-NZ$16.43 Million 320.05%๐Ÿ‡บ๐Ÿ‡ธ USA